CYFIP1

Summary

CYFIP1 (cytoplasmic FMR1 interacting protein 1, HGNC:13759) is a protein-coding gene on chromosome 15q11.2, encoding Cytoplasmic FMR1-interacting protein 1 (Q7L576). Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. It is a selective cancer dependency (DepMap: 11.8% of cell lines).

This gene encodes a protein that regulates cytoskeletal dynamics and protein translation. The encoded protein is a component of the WAVE regulatory complex (WRC), which promotes actin polymerization. This protein also interacts with the synaptic functional regulator FMR1 protein and translation initiation factor 4E to inhibit protein translation. A large chromosomal deletion including this gene is associated with increased risk of schizophrenia and epilepsy in human patients. Reduced expression of this gene has been observed in various human cancers and the encoded protein may inhibit tumor invasion.

Source: NCBI Gene 23191 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 455 total — 80 pathogenic, 8 likely-pathogenic
• Phenotypes (HPO): 4
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 11.8% of screened cell lines
• MANE Select transcript: NM_014608

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13759
Approved symbol	CYFIP1
Name	cytoplasmic FMR1 interacting protein 1
Location	15q11.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0068, P140SRA-1, SHYC
Ensembl gene	ENSG00000273749
Ensembl biotype	protein_coding
OMIM	606322
Entrez	23191

Gene structure

Transcript identifiers

Ensembl transcripts: 40 — 33 protein_coding, 5 retained_intron, 2 nonsense_mediated_decay

ENST00000557890, ENST00000561263, ENST00000610365, ENST00000611832, ENST00000612288, ENST00000613006, ENST00000617556, ENST00000617928, ENST00000619037, ENST00000619290, ENST00000619348, ENST00000621036, ENST00000621105, ENST00000622576, ENST00000900858, ENST00000900859, ENST00000900860, ENST00000900861, ENST00000900862, ENST00000900863, ENST00000900864, ENST00000900865, ENST00000900866, ENST00000900867, ENST00000900868, ENST00000900869, ENST00000900870, ENST00000900871, ENST00000900872, ENST00000919971, ENST00000919972, ENST00000919973, ENST00000919974, ENST00000919975, ENST00000945409, ENST00000945410, ENST00000945411, ENST00000945412, ENST00000945413, ENST00000945414

RefSeq mRNA: 10 — MANE Select: NM_014608 NM_001033028, NM_001287810, NM_001324119, NM_001324120, NM_001324122, NM_001324123, NM_001324124, NM_001324125, NM_001324126, NM_014608

CCDS: CCDS73695, CCDS73696

Canonical transcript exons

ENST00000617928 — 31 exons

Exon	Start	End
ENSE00003508087	22873491	22873729
ENSE00003687751	22874550	22874644
ENSE00003713543	22947003	22947092
ENSE00003716653	22917788	22917935
ENSE00003721953	22943173	22943354
ENSE00003722406	22875199	22875271
ENSE00003723717	22909194	22909313
ENSE00003723866	22932223	22932340
ENSE00003731621	22980287	22980368
ENSE00003732148	22925982	22926107
ENSE00003732797	22910737	22910813
ENSE00003733526	22937104	22937208
ENSE00003734651	22939411	22939507
ENSE00003736360	22927906	22928028
ENSE00003738338	22916477	22916630
ENSE00003738472	22903706	22903905
ENSE00003742719	22944862	22944939
ENSE00003743642	22914726	22914882
ENSE00003744121	22872825	22872972
ENSE00003744369	22944558	22944659
ENSE00003745233	22912179	22912275
ENSE00003746012	22881846	22881936
ENSE00003746709	22933802	22933893
ENSE00003750653	22939192	22939320
ENSE00003750920	22918692	22918858
ENSE00003750958	22892890	22892977
ENSE00003751469	22882868	22883011
ENSE00003751891	22879913	22880043
ENSE00003752006	22867052	22870192
ENSE00003753317	22910520	22910628
ENSE00003754825	22947169	22947291

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 48.7736 / max 428.8543, expressed in 1797 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
148984	45.9884	1795
148983	2.5132	1359
148985	0.2604	133
148981	0.0116	2

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
esophagus squamous epithelium	UBERON:0006920	99.23	gold quality
germinal epithelium of ovary	UBERON:0001304	99.03	gold quality
epithelium of esophagus	UBERON:0001976	99.03	gold quality
gingival epithelium	UBERON:0001949	98.90	gold quality
parietal pleura	UBERON:0002400	98.89	gold quality
visceral pleura	UBERON:0002401	98.89	gold quality
pleura	UBERON:0000977	98.76	gold quality
gingiva	UBERON:0001828	98.71	gold quality
squamous epithelium	UBERON:0006914	98.58	gold quality
oral cavity	UBERON:0000167	98.42	gold quality
tibia	UBERON:0000979	98.37	gold quality
tongue squamous epithelium	UBERON:0006919	98.21	gold quality
palpebral conjunctiva	UBERON:0001812	98.20	gold quality
skin of hip	UBERON:0001554	98.07	gold quality
colonic mucosa	UBERON:0000317	97.95	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.95	gold quality
upper leg skin	UBERON:0004262	97.69	gold quality
caput epididymis	UBERON:0004358	97.59	gold quality
ileal mucosa	UBERON:0000331	97.49	gold quality
mammalian vulva	UBERON:0000997	97.45	gold quality
metanephric glomerulus	UBERON:0004736	97.43	gold quality
epithelial cell of pancreas	CL:0000083	97.41	gold quality
epithelium of mammary gland	UBERON:0003244	97.40	gold quality
renal glomerulus	UBERON:0000074	97.32	gold quality
pericardium	UBERON:0002407	97.31	gold quality
layer of synovial tissue	UBERON:0007616	97.26	gold quality
seminal vesicle	UBERON:0000998	97.25	gold quality
mammary duct	UBERON:0001765	97.24	gold quality
cauda epididymis	UBERON:0004360	97.22	gold quality
penis	UBERON:0000989	97.15	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	30.61
E-HCAD-25	yes	16.69
E-CURD-112	yes	14.79
E-ANND-3	yes	14.01
E-GEOD-111727	no	617.37
E-MTAB-2983	no	397.34
E-CURD-10	no	184.17

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EOMES

miRNA regulators (miRDB)

29 targeting CYFIP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-4756-3P	99.62	66.30	1319
HSA-MIR-513C-5P	99.50	68.42	1730
HSA-MIR-514B-5P	99.50	68.19	1766
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-133A-5P	99.28	69.13	941
HSA-MIR-196A-3P	99.19	67.34	1204
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-1304-3P	98.29	66.44	1207
HSA-MIR-4659A-5P	98.03	66.42	819
HSA-MIR-4659B-5P	98.03	66.84	979
HSA-MIR-1285-5P	98.01	68.71	779
HSA-MIR-1243	97.07	65.44	719
HSA-MIR-6839-5P	96.74	68.29	1088
HSA-MIR-4695-3P	96.71	67.21	836
HSA-MIR-378J	96.44	66.20	1020
HSA-MIR-2114-5P	96.00	64.56	617
HSA-MIR-5739	88.09	63.94	123

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 11.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 28)

• located in the genomic domain between break points 1 and 2 on chromosome 15, of the Prader-Willi/Angelman syndromes (PMID:14508708)
• CRMP-2 transports the Sra-1/WAVE1 complex to axons in a kinesin-1-dependent manner and thereby regulates axon outgrowth and formation (PMID:16260607)
• quantitated mRNA levels of NIPA2, NIPA2,l CYFIP1, and GCP5 in Prader-Willi syndrome and correlated levels with psychological and behavior scales (PMID:16982806)
• Study found that Cyfip1, a subunit of the WAVE complex, which regulates cytoskeletal dynamics, is commonly deleted in human epithelial cancers. (PMID:19524508)
• Protein complexes containing CYFIP/Sra/PIR121 coordinate Arf1 and Rac1 signalling during clathrin-AP-1-coated carrier biogenesis at the trans-golgi network. (PMID:20228810)
• An imbalance of specific isoforms of CYFIP1, an FMRP interaction partner, and CAMK4, a transcriptional regulator of the FMRP gene, modulates risk for autism spectrum disorders. (PMID:24442360)
• haploinsufficiency causes cell polarity defects via WAVE complex destabilization; genetic polymorphism is associated with schizophrenia (PMID:24996170)
• This study confirmed that CYFIP2 were altered in postsynaptic density in patient with schizophrenia. (PMID:25048004)
• Data confirm that CYFIP1 is upregulated in transformed lymphoblastoid cell lines and demonstrate its upregulation in the post-mortem brain from 15q11-13 duplication patients for the first time (PMID:25311365)
• Both mRNA and protein expression levels of Cyfip1 were significantly lower in ALL patients. (PMID:26779626)
• Reduced CYFIP1 in human neural progenitors results in dysregulation of schizophrenia and epilepsy gene networks. (PMID:26824476)
• Hippocampal synapses with reduced Cyfip1 are larger and release neurotransmitter more rapidly. (PMID:26843638)
• rs4778298, a common variant at CYFIP1 is associated with inter-individual variation in surface area across the left supramarginal gyrus. (PMID:27351196)
• we show that stapled peptides targeting the interface between NCKAP1 and CYFIP1 destabilize the WASF3 complex… thereby suppressing invasion and metastasis of breast cancer cells. (PMID:27432794)
• The studies suggest that MNK-eiF4E axis controls the translation of specific mRNAs in cancer metastasis and neuronal synaptic plasticity by a novel mechanism involving the regulation of the translational repressor, CYFIP1. (Review) (PMID:27527252)
• Surprisingly, Rac1 is not located at the binding site on the Sra1 subunit of the WAVE regulatory complex previously identified by mutagenesis and biochemical data. Rather, it binds to a distinct, conserved site on the opposite end of Sra1. (PMID:28949297)
• The expression level of Cyfip1 mRNA was significantly lower in patients with nasopharyngeal carcinoma than in the control samples. Low expression level of Cyfip1 mRNA was significantly associated with invasive range, lymph node metastasis, distant metastases, and clinical stage. (PMID:29534591)
• A novel regulatory mechanism of p53 in early onset breast cancer progression through GAS7-CYFIP1-mediated signaling pathways. (PMID:29706651)
• The current study provides further supports for contribution of CYFIP1/2 in the pathogenesis of autism spectrum disorder (ASD) and potentiates it as a peripheral marker for ASD diagnosis. (PMID:29752658)
• CYFIP1 gene expression was upregulated in the blood of epileptic patients. (PMID:29992499)
• this research identifies the behavioral and molecular consequences of CYFIP1 overexpression. (PMID:31198525)
• The human studies revealed profound deficits in grammatical reasoning, arithmetic reasoning, and working memory in BP1-BP2 (TUBGCP5, CYFIP1, NIPA2, and NIPA1) deletion carriers. (PMID:31202490)
• Evidence for a Contribution of the Nlgn3/Cyfip1/Fmr1 Pathway in the Pathophysiology of Autism Spectrum Disorders. (PMID:31705895)
• Haploinsufficiency of the schizophrenia and autism risk gene Cyfip1 causes abnormal postnatal hippocampal neurogenesis through microglial and Arp2/3 mediated actin dependent mechanisms. (PMID:34031371)
• Cytoplasmic FMR1 interacting protein (CYFIP) family members and their function in neural development and disorders. (PMID:34327661)
• Loss of Function in the Neurodevelopmental Disease and Schizophrenia-Associated Gene CYFIP1 in Human Microglia-like Cells Supports a Functional Role in Synaptic Engulfment. (PMID:37573007)
• Different dysregulations of CYFIP1 and CYFIP2 in distinct types of dementia. (PMID:38128786)
• Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma. (PMID:38427078)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cyfip1	ENSDARG00000044345
mus_musculus	Cyfip1	ENSMUSG00000030447
rattus_norvegicus	Cyfip1	ENSRNOG00000011945
drosophila_melanogaster	Cyfip	FBGN0038320
caenorhabditis_elegans		WBGENE00001579

Paralogs (1): CYFIP2 (ENSG00000055163)

Protein

Protein identifiers

Cytoplasmic FMR1-interacting protein 1 — Q7L576 (reviewed: Q7L576)

Alternative names: Specifically Rac1-associated protein 1, p140sra-1

All UniProt accessions (7): A0A087WU52, A0A087WVZ5, Q7L576, A0A087WWL1, A0A087WWY5, A0A087WZ89, H0YL50

UniProt curated annotations — full annotation on UniProt →

Function. Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit is an adapter between EIF4E and FMR1. Promotes the translation repression activity of FMR1 in brain probably by mediating its association with EIF4E and mRNA. Regulates formation of membrane ruffles and lamellipodia. Plays a role in axon outgrowth. Binds to F-actin but not to RNA. Part of the WAVE complex that regulates actin filament reorganization via its interaction with the Arp2/3 complex. Actin remodeling activity is regulated by RAC1. Regulator of epithelial morphogenesis. As component of the WAVE1 complex, required for BDNF-NTRK2 endocytic trafficking and signaling from early endosomes. May act as an invasion suppressor in cancers.

Subunit / interactions. Component of the WAVE1 complex composed of ABI2, CYFIP1 or CYFIP2, BRK1, NCKAP1 and WASF1/WAVE1. Within the complex, a heterodimer containing NCKAP1 and CYFIP1 interacts with a heterotrimer formed by WAVE1, ABI2 and BRK1. Component of the CYFIP1-EIF4E-FMR1 complex which is composed of CYFIP, EIF4E and FMR1. Interacts with FMR1 but does not bind to related proteins FXR1 or FXR2. Interaction with EIF4E stimulates FMR1 binding. Component of the WAVE2 complex composed of ABI1, CYFIP1/SRA1, NCKAP1/NAP1 (NCKAP1l/HEM1 in hematopoietic cells) and WASF2/WAVE2. Interacts with the active GTP-bound form of RAC1. Interacts through its C-terminus with the C-terminus of DPYSL2/CRMP2 which is necessary for DPYSL2-induced axon outgrowth. Interacts with NYAP1, NYAP2 and MYO16. Interacts with TMEM108 (via N-terminus); the interaction associates TMEM108 with the WAVE1 complex.

Subcellular location. Cytoplasm. Perinuclear region. Cell projection. Lamellipodium. Ruffle. Synapse. Synaptosome.

Miscellaneous. Breakpoint hotspot for the Prader-Willi/Angelman syndromes and may be implicated in autism. Commonly altered in tumors.

Similarity. Belongs to the CYFIP family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q7L576-1	1, 3	yes
Q7L576-2	2, 4
Q7L576-3	3, 5

RefSeq proteins (10): NP_001028200, NP_001274739, NP_001311048, NP_001311049, NP_001311051, NP_001311052, NP_001311053, NP_001311054, NP_001311055, NP_055423* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008081	Cytoplasmic_FMR1-int	Family
IPR009828	CYRIA/CYRIB_Rac1-bd	Domain

Pfam: PF05994, PF07159

UniProt features (119 total): helix 68, strand 19, turn 10, mutagenesis site 9, sequence conflict 4, splice variant 3, sequence variant 3, modified residue 2, chain 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
3P8C	X-RAY DIFFRACTION	2.29
4N78	X-RAY DIFFRACTION	2.43
7USC	ELECTRON MICROSCOPY	3
7USD	ELECTRON MICROSCOPY	3
7USE	ELECTRON MICROSCOPY	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7L576-F1	90.24	0.72

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 583, 1234

Mutagenesis-validated functional residues (9):

Position	Phenotype
190	reduced interaction with rac1.
434	reduced interaction with rac1; when associated with a-626.
626	reduced interaction with rac1; when associated with k-434.
632	reduced interaction with rac1.
697	constitutive induction of the formation of actin filaments; when associated with d-704.
704	constitutive induction of the formation of actin filaments; when associated with d-697.
841	constitutive induction of the formation of actin filaments; when associated with 844-a-a-845.
844–845	constitutive induction of the formation of actin filaments; when associated with a-841.
179	reduced interaction with rac1.

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation
R-HSA-4420097	VEGFA-VEGFR2 Pathway
R-HSA-5663213	RHO GTPases Activate WASPs and WAVEs
R-HSA-6798695	Neutrophil degranulation
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-9013404	RAC2 GTPase cycle
R-HSA-9013408	RHOG GTPase cycle
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-9664422	FCGR3A-mediated phagocytosis

MSigDB gene sets: 385 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_COGNITION, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_NEURON_PROJECTION_EXTENSION, GOBP_REGULATION_OF_ACTIN_NUCLEATION, GOCC_SECRETORY_GRANULE, GOBP_GROWTH, GOBP_NEUROGENESIS, GOCC_RUFFLE, GOMF_GTPASE_BINDING, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS

GO Biological Process (20): cell morphogenesis (GO:0000902), regulation of translation (GO:0006417), axon guidance (GO:0007411), regulation of cell shape (GO:0008360), positive regulation of lamellipodium assembly (GO:0010592), Rac protein signal transduction (GO:0016601), lamellipodium assembly (GO:0030032), regulation of actin filament polymerization (GO:0030833), ruffle organization (GO:0031529), axon extension (GO:0048675), cognition (GO:0050890), positive regulation of neurotrophin TRK receptor signaling pathway (GO:0051388), dendrite extension (GO:0097484), regulation of translation at postsynapse, modulating synaptic transmission (GO:0099578), regulation of modification of postsynaptic actin cytoskeleton (GO:1905274), positive regulation of Arp2/3 complex-mediated actin nucleation (GO:2000601), nervous system development (GO:0007399), negative regulation of translation (GO:0017148), cell differentiation (GO:0030154), neuron projection development (GO:0031175)

GO Molecular Function (6): RNA 7-methylguanosine cap binding (GO:0000340), translation repressor activity (GO:0030371), small GTPase binding (GO:0031267), actin filament binding (GO:0051015), actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (17): ruffle (GO:0001726), extracellular region (GO:0005576), cytosol (GO:0005829), focal adhesion (GO:0005925), lamellipodium (GO:0030027), SCAR complex (GO:0031209), secretory granule lumen (GO:0034774), specific granule lumen (GO:0035580), neuron projection (GO:0043005), synapse (GO:0045202), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), postsynapse (GO:0098794), tertiary granule lumen (GO:1904724), cytoplasm (GO:0005737), cell leading edge (GO:0031252), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
RHO GTPase cycle	4
Fcgamma receptor (FCGR) dependent phagocytosis	1
Signaling by VEGF	1
RHO GTPase Effectors	1
Innate Immune System	1
Leishmania phagocytosis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	7
translation	3
plasma membrane bounded cell projection	3
cytoplasm	3
axonogenesis	2
plasma membrane bounded cell projection organization	2
neuron projection extension	2
cell leading edge	2
anatomical structure morphogenesis	1
post-transcriptional regulation of gene expression	1
regulation of protein metabolic process	1
neuron projection guidance	1
regulation of cell morphogenesis	1
regulation of biological quality	1
regulation of lamellipodium assembly	1
lamellipodium assembly	1
positive regulation of plasma membrane bounded cell projection assembly	1
positive regulation of lamellipodium organization	1
small GTPase-mediated signal transduction	1
lamellipodium organization	1
plasma membrane bounded cell projection assembly	1
regulation of actin polymerization or depolymerization	1
actin filament polymerization	1
regulation of protein polymerization	1
nervous system process	1
positive regulation of signal transduction	1
neurotrophin TRK receptor signaling pathway	1
regulation of neurotrophin TRK receptor signaling pathway	1
chemical synaptic transmission	1
postsynapse	1
postsynaptic modulation of chemical synaptic transmission	1
regulation of translation at synapse, modulating synaptic transmission	1
regulation of translation at postsynapse	1
modification of postsynaptic actin cytoskeleton	1
regulation of modification of postsynaptic structure	1
Arp2/3 complex-mediated actin nucleation	1
regulation of Arp2/3 complex-mediated actin nucleation	1
positive regulation of actin nucleation	1
system development	1
regulation of translation	1

Protein interactions and networks

STRING

1668 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYFIP1	NCKAP1	Q9Y2A7	998
CYFIP1	FMR1	Q06787	998
CYFIP1	BRK1	Q8WUW1	998
CYFIP1	FXR2	P51116	997
CYFIP1	ABI1	Q8IZP0	997
CYFIP1	ABI2	Q9NYB9	996
CYFIP1	FXR1	P51114	996
CYFIP1	NCKAP1L	P55160	995
CYFIP1	WASF1	Q92558	995
CYFIP1	EIF4E	P06730	988
CYFIP1	WASF2	Q9Y6W5	981
CYFIP1	NIPA2	Q8N8Q9	973
CYFIP1	TUBGCP5	Q96RT8	973
CYFIP1	NIPA1	Q7RTP0	965
CYFIP1	ABI3	Q9P2A4	963

IntAct

218 interactions, top by confidence:

A	B	Type	Score
NCKAP1	CYFIP1	psi-mi:“MI:0915”(physical association)	0.900
CYFIP1	NCKAP1	psi-mi:“MI:0407”(direct interaction)	0.900
CYFIP1	NCKAP1	psi-mi:“MI:0915”(physical association)	0.900
	EIF4E	psi-mi:“MI:0914”(association)	0.880
ABI2	CYFIP1	psi-mi:“MI:0915”(physical association)	0.870
BAIAP2	YWHAQ	psi-mi:“MI:0914”(association)	0.740
BRK1	HSBP1	psi-mi:“MI:0914”(association)	0.740
CYFIP1	ABI1	psi-mi:“MI:0915”(physical association)	0.740
NCKAP1	YWHAH	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
IKBIP	SNAPIN	psi-mi:“MI:0914”(association)	0.670
NCK2	SH3PXD2B	psi-mi:“MI:0914”(association)	0.640
WASF1	CYFIP1	psi-mi:“MI:0914”(association)	0.640
BRK1	CYFIP1	psi-mi:“MI:0914”(association)	0.640

BioGRID (270): CYFIP1 (Affinity Capture-MS), CYFIP1 (Affinity Capture-MS), CYFIP1 (Affinity Capture-MS), CYFIP1 (Affinity Capture-MS), CYFIP1 (Affinity Capture-MS), CYFIP1 (Affinity Capture-MS), BZW2 (Co-fractionation), CYFIP1 (Co-fractionation), CYFIP1 (Co-fractionation), CYFIP1 (Co-fractionation), CYFIP1 (Co-fractionation), CYFIP1 (Co-fractionation), CYFIP1 (Co-fractionation), FNBP1L (Co-fractionation), TRIP10 (Co-fractionation)

ESM2 similar proteins: A1CGW7, A1CXW3, A1Z7L1, A7RU46, B0S6R1, F1QJX5, F1QN74, F6WXT2, O44518, P28660, P55160, P55161, P55162, P55163, Q0CL68, Q16X15, Q23658, Q24134, Q299G2, Q2UG94, Q4WNQ6, Q54IR8, Q54R74, Q5R414, Q5S2C3, Q5SQX6, Q5U430, Q5XHG1, Q60PC0, Q640K3, Q6GQD1, Q6PFJ7, Q6PI53, Q6UK63, Q6ZBH9, Q7L576, Q7Q6D9, Q7TMB8, Q869Q3, Q8IQV9

Diamond homologs: O44518, Q299G2, Q5R414, Q5SQX6, Q6GQD1, Q6UK63, Q7L576, Q7TMB8, Q90YM8, Q96F07, Q9VF87, Q5S2C3

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CYFIP1	“form complex”	“WRC complex”	binding
CYFIP1	“up-regulates activity”	NHS	binding
CYFIP1	“form complex”	“WAVE complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 168 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RHO GTPases Activate WASPs and WAVEs	15	42.9×	8e-19
Activation of BAD and translocation to mitochondria	5	34.3×	8e-06
Parasite infection	10	31.2×	5e-11
Leishmania phagocytosis	10	31.2×	5e-11
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	5	30.3×	1e-05
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	5	30.3×	1e-05
FCGR3A-mediated phagocytosis	16	27.0×	7e-17
Regulation of actin dynamics for phagocytic cup formation	16	26.6×	7e-17

GO biological processes:

GO term	Partners	Fold	FDR
Rac protein signal transduction	7	27.3×	3e-06
positive regulation of lamellipodium assembly	5	20.9×	6e-04
lamellipodium assembly	6	18.5×	2e-04
positive regulation of actin filament polymerization	7	16.1×	1e-04
cell motility	5	13.9×	2e-03
neuron projection morphogenesis	7	13.4×	2e-04
small GTPase-mediated signal transduction	6	7.6×	9e-03
intracellular protein localization	10	7.3×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

455 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	80
Likely pathogenic	8
Uncertain significance	233
Likely benign	34
Benign	37

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1012382	GRCh37/hg19 15q11.2-12(chr15:22833525-27193380)x4	Pathogenic
1175875	GRCh37/hg19 15q11.2(chr15:22833525-23264865)x1	Pathogenic
1328464	GRCh37/hg19 15q11.2(chr15:22832874-23223352)x1	Pathogenic
1330198	GRCh37/hg19 15q11.2(chr15:22743127-23246000)x1	Pathogenic
1339977	GRCh37/hg19 15q11.2(chr15:22770421-23625677)x1	Pathogenic
1340320	GRCh37/hg19 15q11.2(chr15:22770422-23195725)x1	Pathogenic
146208	GRCh38/hg38 15q11.2(chr15:22787972-23107440)x1	Pathogenic
1694765	GRCh37/hg19 15q11.2(chr15:22833525-23265556)x1	Pathogenic
1705939	GRCh37/hg19 15q11.2(chr15:22770421-25648680)x1	Pathogenic
1707411	Single allele	Pathogenic
1708197	GRCh37/hg19 15q11.2(chr15:22770421-23288487)x3	Pathogenic
1708267	Single allele	Pathogenic
1711393	GRCh37/hg19 15q11.2(chr15:22736246-23265381)x1	Pathogenic
1808466	GRCh37/hg19 15q11.2(chr15:22770422-23082442)x1	Pathogenic
1808506	GRCh37/hg19 15q11.2(chr15:22770422-23082328)x1	Pathogenic
1879312	GRCh37/hg19 15q11.2(chr15:22833525-23262343)x1	Pathogenic
1879313	GRCh37/hg19 15q11.2(chr15:22833525-23264190)x1	Pathogenic
2498628	GRCh37/hg19 15q11.2(chr15:22070540-23262343)x1	Pathogenic
2506528	GRCh37/hg19 15q11.2(chr15:22833525-23412276)	Pathogenic
252972	GRCh37/hg19 15q11.2(chr15:22427966-23226254)x1	Pathogenic
2570914	GRCh37/hg19 15q11.2(chr15:22833499-23577516)x1	Pathogenic
2570915	GRCh37/hg19 15q11.2(chr15:22833525-23412276)x1	Pathogenic
2574676	GRCh37/hg19 15q11.2(chr15:22770421-23282799)	Pathogenic
2574691	GRCh37/hg19 15q11.2(chr15:22770421-23195725)	Pathogenic
2580327	GRCh37/hg19 15q11.2(chr15:22744149-23246340)x1	Pathogenic
2663903	GRCh38/hg38 15q11.2(chr15:22542702-23121344)x1	Pathogenic
2671614	Single allele	Pathogenic
2685502	GRCh37/hg19 15q11.2(chr15:22770422-23679133)x1	Pathogenic
3024383	GRCh38/hg38 15q11.2(chr15:22633497-23084434)	Pathogenic
3024585	GRCh37/hg19 15q11.2(chr15:22757538-23411062)x1	Pathogenic

SpliceAI

6245 predictions. Top by Δscore:

Variant	Effect	Δscore
15:22870191:G:GG	acceptor_gain	1.0000
15:22870191:GCC:G	acceptor_gain	1.0000
15:22870192:A:AG	acceptor_gain	1.0000
15:22870199:T:TA	acceptor_gain	1.0000
15:22872842:A:G	donor_gain	1.0000
15:22872971:GGCA:G	acceptor_gain	1.0000
15:22873488:G:GG	donor_gain	1.0000
15:22873490:GA:G	donor_gain	1.0000
15:22873493:GTCGA:G	donor_gain	1.0000
15:22874643:G:GG	acceptor_gain	1.0000
15:22874644:A:AG	acceptor_gain	1.0000
15:22875195:T:G	donor_loss	1.0000
15:22875196:G:T	donor_loss	1.0000
15:22875197:GGT:G	donor_loss	1.0000
15:22875198:AGG:A	donor_loss	1.0000
15:22875199:AAGG:A	donor_loss	1.0000
15:22875270:G:C	acceptor_loss	1.0000
15:22875270:G:GA	acceptor_gain	1.0000
15:22875270:GT:G	acceptor_gain	1.0000
15:22875270:GTCT:G	acceptor_gain	1.0000
15:22875271:A:AG	acceptor_gain	1.0000
15:22875273:CTA:C	acceptor_loss	1.0000
15:22875274:TCTA:T	acceptor_loss	1.0000
15:22879910:G:A	donor_loss	1.0000
15:22879910:G:GG	donor_gain	1.0000
15:22879911:GG:G	donor_gain	1.0000
15:22879912:TG:T	donor_gain	1.0000
15:22879912:TGG:T	donor_loss	1.0000
15:22879913:CTG:C	donor_gain	1.0000
15:22879914:CCTG:C	donor_gain	1.0000

AlphaMissense

8315 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:22872956:C:A	G1156W	1.000
15:22872961:C:A	G1154V	1.000
15:22872961:C:T	G1154D	1.000
15:22873544:A:C	S1132R	1.000
15:22873544:A:T	S1132R	1.000
15:22873546:T:G	S1132R	1.000
15:22873549:A:G	W1131R	1.000
15:22873549:A:T	W1131R	1.000
15:22875249:A:G	L1022P	1.000
15:22879949:G:C	N1002K	1.000
15:22879949:G:T	N1002K	1.000
15:22879953:C:T	G1001E	1.000
15:22879954:C:A	G1001W	1.000
15:22879954:C:G	G1001R	1.000
15:22879954:C:T	G1001R	1.000
15:22879962:C:G	R998P	1.000
15:22880016:A:G	L980P	1.000
15:22881858:A:G	Y967H	1.000
15:22903706:C:G	R863P	1.000
15:22903754:A:G	L847P	1.000
15:22910806:A:G	L697P	1.000
15:22912184:C:G	A693P	1.000
15:22914775:A:G	W646R	1.000
15:22914775:A:T	W646R	1.000
15:22914797:G:C	F638L	1.000
15:22914797:G:T	F638L	1.000
15:22914798:A:G	F638S	1.000
15:22914799:A:G	F638L	1.000
15:22914822:A:G	L630P	1.000
15:22914828:A:G	L628P	1.000

dbSNP variants (sampled 300 via entrez): RS1000047677 (15:22897596 G>A), RS1000050554 (15:22917952 G>A,C), RS1000081339 (15:22978462 A>C), RS1000117353 (15:22898827 C>T), RS1000118346 (15:22953587 T>A), RS1000131523 (15:22973267 T>C), RS1000137424 (15:22962665 A>C), RS1000166391 (15:22889509 C>A), RS1000179803 (15:22928290 G>C), RS1000214019 (15:22949044 C>G,T), RS1000218608 (15:22966280 G>A), RS1000243436 (15:22869054 A>T), RS1000244864 (15:22928185 A>G), RS1000260259 (15:22932428 G>A,T), RS1000293716 (15:22879361 C>T)

Disease associations

OMIM: gene MIM:606322 | disease phenotypes: MIM:615656, MIM:241550, MIM:257350, MIM:608636, MIM:209850, MIM:108800, MIM:176270, MIM:181500

GenCC curated gene-disease

Mondo (15): chromosome 15q11.2 deletion syndrome (MONDO:0014294), neurodevelopmental disorder (MONDO:0700092), hypoplastic left heart syndrome 1 (MONDO:0009433), cystic hygroma (MONDO:0009761), 15q11q13 microduplication syndrome (MONDO:0012081), epilepsy (MONDO:0005027), autism spectrum disorder (MONDO:0005258), strabismus (MONDO:0003432), autism (MONDO:0005260), atrial septal defect (MONDO:0006664), Prader-Willi syndrome (MONDO:0008300), thrombocytopenia (MONDO:0002049), hypertensive disorder (MONDO:0005044), obesity disorder (MONDO:0011122), schizophrenia (MONDO:0005090)

Orphanet (10): 15q11.2 microdeletion syndrome (Orphanet:261183), Hypoplastic left heart syndrome (Orphanet:2248), 15q11q13 microduplication syndrome (Orphanet:238446), Interatrial communication (Orphanet:1478), Prader-Willi syndrome (Orphanet:739), Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), Cystic hygroma (Orphanet:79486), NON RARE IN EUROPE: Autism (Orphanet:106), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0000717	Autism
HP:0000822	Hypertension
HP:0001513	Obesity
HP:0100753	Schizophrenia

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST006979_1017	Heel bone mineral density	1.000000e-12
GCST009615_16	Triglyceride levels x loop diuretics use interaction	4.000000e-07
GCST009615_17	Triglyceride levels x loop diuretics use interaction	3.000000e-06
GCST010116_1	World class endurance athleticism	9.000000e-06
GCST012306_11	Bipolar disorder	1.000000e-06
GCST90002401_87	Platelet distribution width	1.000000e-21

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0004530	triglyceride measurement
EFO:0007818	athletic endurance measurement
EFO:0007984	platelet component distribution width

MeSH disease descriptors (9)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500
D004827	Epilepsy	C10.228.140.490
D006344	Heart Septal Defects, Atrial	C14.240.400.560.375; C14.280.400.560.375; C16.131.240.400.560.375
D006973	Hypertension	C14.907.489
D018191	Lymphangioma, Cystic	C04.557.375.450.450
D065886	Neurodevelopmental Disorders	F03.625
D011218	Prader-Willi Syndrome	C10.597.606.360.690; C16.131.077.730; C16.131.260.700; C16.320.180.700; C16.320.447.500; C18.654.726.750.500.740
D013285	Strabismus	C10.292.562.887; C11.590.810
D013921	Thrombocytopenia	C15.378.140.855; C15.378.243.937

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724762 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.25	Kd	5.638	nM	CHEMBL3752910
8.25	ED50	5.638	nM	CHEMBL3752910
5.56	Kd	2745	nM	CHEMBL5653589
5.56	ED50	2745	nM	CHEMBL5653589

PubChem BioAssay actives

2 with measured affinity, of 10 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148189: Binding affinity to human CYFIP1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0056	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148189: Binding affinity to human CYFIP1 incubated for 45 mins by Kinobead based pull down assay	kd	2.7453	uM

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	4
bisphenol A	affects cotreatment, increases methylation, increases expression	2
entinostat	decreases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment, increases expression	2
Smoke	decreases expression	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
pyrogallol 1,3-dimethyl ether	decreases expression, affects cotreatment	1
beta-lapachone	decreases expression, increases expression	1
arsenite	affects binding, decreases reaction	1
sodium bichromate	decreases expression	1
cobaltous chloride	decreases expression	1
benzo(e)pyrene	increases methylation	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
belinostat	decreases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases expression	1
LDN 193189	increases expression, affects cotreatment	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Vorinostat	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Benzoates	decreases expression	1
Caffeine	decreases phosphorylation	1
Doxorubicin	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651231	Binding	Binding affinity to human CYFIP1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00004637	PHASE4	COMPLETED	Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
NCT00043914	PHASE4	COMPLETED	Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00132223	PHASE4	UNKNOWN	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients
NCT00133081	PHASE4	UNKNOWN	Study to Improve the Treatment of Epilepsy (SITE)
NCT00137709	PHASE4	UNKNOWN	Hormone Profiles in Adults With Newly Diagnosed Epilepsy
NCT00154076	PHASE4	COMPLETED	A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
NCT00165828	PHASE4	TERMINATED	Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
NCT00181116	PHASE4	COMPLETED	Levetiracetam for Benign Rolandic Epilepsy
NCT00207935	PHASE4	COMPLETED	Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
NCT00215592	PHASE4	COMPLETED	Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
NCT00266604	PHASE4	COMPLETED	A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
NCT00288639	PHASE4	COMPLETED	Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00312676	PHASE4	UNKNOWN	Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote
NCT00323947	PHASE4	COMPLETED	Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
NCT00385411	PHASE4	COMPLETED	Study of Valproate in Young Patients Suffering From Epilepsy
NCT00522418	PHASE4	TERMINATED	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
NCT00537940	PHASE4	COMPLETED	Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
NCT00552526	PHASE4	UNKNOWN	Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
NCT00564915	PHASE4	COMPLETED	RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
NCT00571155	PHASE4	COMPLETED	Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery
NCT00572195	PHASE4	COMPLETED	RNS® System LTT Study
NCT00610532	PHASE4	TERMINATED	Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
NCT00630357	PHASE4	COMPLETED	Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
NCT00630630	PHASE4	COMPLETED	Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
NCT00630968	PHASE4	COMPLETED	S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00631150	PHASE4	COMPLETED	A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00659958	PHASE4	COMPLETED	ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
NCT00713622	PHASE4	COMPLETED	Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
NCT00807989	PHASE4	COMPLETED	The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
NCT00832884	PHASE4	COMPLETED	The Safety of Intravenous Lacosamide
NCT00869622	PHASE4	COMPLETED	Antiepileptic Drugs and Osteoporotic Prevention Trial
NCT00896987	PHASE4	COMPLETED	Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies
NCT00952081	PHASE4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT01118455	PHASE4	TERMINATED	Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
NCT01127165	PHASE4	COMPLETED	Low and High Dose Zonisamide in Children as Monotherapy
NCT01127256	PHASE4	COMPLETED	Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation
NCT01140867	PHASE4	COMPLETED	Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
NCT01175954	PHASE4	COMPLETED	Cognitive and Behavioral Effects of Lacosamide